Up and Coming
This feature highlights changes in clinical research organizations’ personnel.
Alkahest has named Robert Klein chief business officer. Klein was previously chief business officer at Complete Genomics.
Apellis Pharmaceuticals has named Lucia Celona as chief people officer. Celona most recently served as chief HR and communications officer at Bioverativ, a Sanofi company.
Marcelo Cheresky has been appointed senior vice president, rare disease commercial operations, at CANBridge Pharmaceuticals. Cheresky was most recently vice president, emerging markets, at Bioverativ, a Sanofi company.
Paolo Tombesi has been named chief financial officer at Epizyme. Tombesi was most recently CFO at Insmed.
Mark Avagliano has been appointed chief business officer at G1 Therapeutics. Avagliano was previously vice president, corporate development, at Pfizer.
Health Union has announced Will Rompala as chief technology officer. Rompala was formerly chief technology officer at Sidecar.
Paul Frohna has been appointed chief medical officer at ImCheck Therapeutics. Frohna was previously chief medical officer at Bioniz Therapeutics.
Maverick Therapeutics has appointed Chulani Karunatilake senior vice president of technical operations. Karunatilake was previously with Nektar Therapeutics, where he established and led the Biologics CMC division.
Obsidian Therapeutics has named Catherine Stehman-Breen chief development officer, Ryan Daws has been hired as chief financial officer and head of business development, and Karen Brown has been appointed senior vice president, intellectual property and legal affairs. Stehman-Breen most recently served as chief medical officer at Dyne Therapeutics and Disarm Therapeutics. Daws was most recently managing director in the Healthcare Investment Banking Group with Robert W. Baird & Co. Brown was previously vice president and chief intellectual property counsel at Ironwood Pharmaceuticals.
Passage Bio has announced the appointment of Jill Quigley as chief operating officer and general counsel and Alex Fotopoulos as chief technical officer. Quigley was formerly chief executive officer and general counsel at Nutrinia. Fotopoulos previously held the position of senior vice president, technical operations with Dimension Therapeutics.
Heather Kirkby has been appointed chief people officer at Recursion Pharmaceuticals. Kirkby was formerly vice president of talent development at Intuit.
Cris Calsada has been named chief financial officer at Regulus Therapeutics, effective August 30. Calsada was most recently chief financial officer at Sanifit.
RenalytixAI has named Thomas McLain as president and chief commercial officer. McLain most recently held the role of general manager at Exosome Diagnostics.
Kris Elverum has been appointed senior vice president of business development and strategy at Rubius Therapeutics. Elverum was most recently SVP of corporate development at Turnstone Biologics.
SS&C Technologies Holdings has named Sean Hogan as president of SS&C Health. Hogan was formerly the general manager, healthcare and life sciences, at IBM.
Gary Loeb has been named executive vice president and general counsel at Sangamo Therapeutics. Loeb previously was general counsel, corporate secretary and chief compliance officer at Achaogen.
Tridiuum has appointed Paul Castaldo senior vice president of corporate development. Castaldo was previously regional behavioral health care leader with Kaiser Permanente.
Verastem Oncology has announced the appointment of Brian Stuglik as chief executive officer. Stuglik was previously global vice president and chief marketing officer, oncology, at Eli Lilly.
Vivera Pharmaceuticals has named Greg Cervantes director of government affairs and Brad Townend has been appointed executive creative director. Cervantes is the former mayor of the city of Coachella, California. Townend previously held the position of creative director at Allergan.
Satyavrat Shukla has been named chief financial officer at Ziopharm Oncology. Shukla most recently served as global head of corporate finance for Vertex Pharmaceuticals.